You are here

  • Home
  • Archive
  • Volume 73, Issue 6
  • Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al

Article Text

Article menu
Download PDFPDF
Electronic pages
Correspondence
Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al
  1. Markus Bredemeier
  1. Correspondence to Dr Markus Bredemeier, Rheumatology Service, Hospital Nossa Senhora da Conceição—Grupo Hospitalar Conceição, Av. Francisco Trein 596, sala 2048, Bloco H, Porto Alegre 91350-200, Brazil; markbred{at}terra.com.br

https://doi.org/10.1136/annrheumdis-2014-205399

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with interest the paper by Vital et al,1 a pilot study testing the efficacy of an extra dose of rituximab (completing 3×1000 mg over 4 weeks) in comparison with the standard-dose regimen (2×1000 mg) in rheumatoid arthritis patients with incomplete depletion of B cells after a first 1000 mg dose of rituximab (RTX). The study represents an advance in the knowledge about the effects of RTX, but I have some concerns about the interpretation …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles

    • Electronic pages
      Response to Dr Bredemeier's letter
      Edward M Vital Shouvik Dass Maya H Buch Andrew C Rawstron Paul Emery
      Annals of the Rheumatic Diseases 2014; 73 e34-e34 Published Online First: 14 Mar 2014. doi: 10.1136/annrheumdis-2014-205405